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cyclophosphamide (A/C) were significant risks for over-
all nausea. Indeed, the control of delayed nausea was 
extremely poor in the first cycle of A/C, although there was 
no difference in the control of nausea among MEC.
Conclusion Antiemetic medication in consideration of the 
risk factors is required to improve the control of nausea.
Keywords Outpatient cancer chemotherapy · Nausea · 
Emetic risk · Risk analysis · Adherence to guideline
Introduction
Chemotherapy-induced nausea and vomiting (CINV) 
were the first and second most distressing adverse events 
in the past [1]. Nausea and vomiting severely impair the 
patient’s quality of life, which may lead to the discon-
tinuance of therapy. However, the rank order of nausea 
and vomiting has dropped [2] since the development of 
5-hydroxytryptamine-3 (5-HT3) receptor antagonists and 
the prevalence of the American Society of Clinical Oncol-
ogy (ASCO) clinical practice guideline for antiemesis 
[3]. Subsequently, with the development of novel classes 
of antiemetic drugs such as neurokinin 1(NK1) receptor 
antagonists, including aprepitant, and palonosetron, a sec-
ond-generation 5-HT3 receptor antagonist, the antiemetic 
guideline has been revised by several international societies 
for clinical oncology, including ASCO [4], Multinational 
Association of Supportive Care in Cancer (MASCC) [5], 
National Comprehensive Cancer Network (NCCN) [6], and 
Japanese Society of Clinical Oncology (JSCO) [7].
However, guideline-consistent antiemetic medication 
is not always widely used in clinical practice, a so-called 
evidence–practice gap [8]. Gomez et al. [9] reported, in 
patients who received high emetic risk chemotherapy 
Abstract 
Background Control of chemotherapy-induced nausea is 
still incomplete, regardless of adherence to the antiemetic 
guideline. The present study was designed to assess the 
control rates of nausea and vomiting in the outpatient 
chemotherapy clinic and to determine risk factors for 
nausea.
Methods A single-center prospective observational study 
was carried out in 779 patients who received 5511 chem-
otherapy cycles from January 2013 to December 2014 in 
the outpatient chemotherapy clinic. A checklist for adverse 
events was provided to all patients, and nausea and vomit-
ing were monitored on the next visit. Complete protection 
from nausea and vomiting during acute (within 24 h) and 
delayed (during 2–7 days) periods was assessed.
Results Under the condition of 76–99 % rates of adher-
ence to the Japanese Society of Clinical Oncology guide-
line for antiemesis, the rates of complete protection from 
acute and delayed nausea in the first cycle of chemother-
apy were 60 % and 45 %, respectively, for high emetic 
risk chemotherapy (HEC), and 85 % and 70 % for mod-
erate emetic risk chemotherapy (MEC). The rates were 
improved in the overall cycles. On the other hand, vomiting 
was well controlled, in which complete protection ranged 
from 83 % (HEC) to 99 % (minimum). A multivariate 
analysis indicated that being female, age less than 60 years, 
high or moderate risk chemotherapy, and anthracycline/
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(HEC) or moderate emetic risk chemotherapy (MEC), that 
the use of 5-HT3 receptor antagonist with dexamethasone 
is 60–90 %, whereas the use of a NK1 antagonist is much 
less common (<10 %). Hori et al. [10] also reported by a 
nationwide survey of 9978 patients receiving 81,739 chem-
otherapy cycles from 39 Japanese hospitals that the rates of 
adherence to the JSCO guideline during acute and delayed 
periods are 28.1 % and 9.7 %, respectively, for HEC, and 
7.2 % and 6.9 %, respectively, for MEC.
It has been demonstrated that adherence to the antiemetic 
guideline improves the control of CINV [11–13]. Chan et al. 
[11] reported in 361 breast cancer patients receiving anthracy-
cline-based chemotherapy that the adherence to the antiemetic 
guideline is 57.9 % and that the complete control of CINV is 
better in the guideline-consistent group than in the guideline-
inconsistent group, indicating that adherent patients were 
more likely to achieve complete control of CINV [adjusted 
odds ratio (OR) 1.74, 95 % confidence interval (CI) 1.01–3.01, 
P = 0.048]. Aapro et al. [12] also reported in 991 patients 
receiving the first cycle of HEC or MEC that the complete 
response (no vomiting and no rescue) is significantly better 
in the guideline-consistent group than in the guideline-incon-
sistent group (59.9 % vs. 50.7 %, P = 0.008), resulting in the 
adjusted odds ratio of 1.43 (95 % CI 1.04–1.97, P = 0.027). 
We also previously reported in 125 colorectal cancer patients 
receiving the first cycle of MEC such as levofolinate, fluoro-
uracil, oxaliplatin (mFOLFOX6) and levofolinate, fluoroura-
cil, irinotecan (FOLFIRI) regimen that the complete control of 
nausea but not vomiting is significantly better in the guideline-
consistent group than in the guideline-inconsistent (lack of 
dexamethasone on days 2 and 3) group (74 % vs. 56 % for 
nausea, P < 0.05; 94 % vs. 91 % for vomiting) [14].
On the other hand, cancer chemotherapy is currently 
shifting from inpatient admission to the outpatient setting. 
Chemotherapy-induced vomiting is almost preventable in 
the outpatient setting by the addition of NK1 receptor antag-
onists and 5-HT3 receptor antagonists to the standard medi-
cation, although nausea remains a distressing adverse drug 
reaction [15, 16]. In the present study, the antiemetic medi-
cation consistent with the JSCO guideline has been imple-
mented in our outpatient chemotherapy clinic, and the rates 
of complete protection of CINV were subsequently investi-
gated. Risk analysis for overall nausea was also carried out.
Patients and methods
Patients
There were 9590 visits for cancer chemotherapy in our out-
patient chemotherapy clinic during the 2 years from Janu-
ary 2013 to December 2014; among these, chemotherapy 
was carried out in 8206 visits, thereby indicating a 14.4 % 
discontinuance rate. The actual number of patients counted 
by the patient ID number was 779 and the number of 
chemotherapy cycles was 5577. Health professionals such 
as pharmacists and nurses were in charge of provision of 
drug information and safety precaution in daily life and of 
monitoring adverse drug reactions to all patients in our out-
patient chemotherapy clinic. Patient consultation was car-
ried out in 8206 visits (100 %), but the CINV data were 
obtained from 5511 chemotherapy cycles. Thus, data from 
98.8 % of the chemotherapy cycles were subjected to anal-
ysis in the present study.
The present study was carried out in accordance with the 
guidelines for the care for human study adopted by the Eth-
ics Committee of the Gifu Graduate School of Medicine, 
and notified by the Japanese Government (approved no. 
26-153 of the Institutional Review Board).
Adherence to the Japanese guideline for the use 
of antiemetic drugs
According to the JSCO clinical practice guideline for 
antiemesis, the use of antiemetic drugs was promoted for 
prevention of CINV: the combination of 5-HT3 receptor 
antagonist, aprepitant, and dexamethasone was used before 
chemotherapy and a combination of aprepitant and dexa-
methasone was provided on days 2 and 3, and dexametha-
sone on day 4 for high emetic risk chemotherapy (HEC), a 
combination of 5-HT3 receptor antagonist and dexametha-
sone was taken before chemotherapy, and dexamethasone 
was prescribed on days 2 and 3 for moderate emetic risk 
chemotherapy (MEC), and dexamethasone was adminis-
tered only before chemotherapy for low emetic risk chemo-
therapy. No routine antiemetic drug was provided for preven-
tion of minimum risk chemotherapy. Health professionals 
made extensive efforts in facilitating the use of appropriate 
antiemetic premedication by inclusion of antiemetic regi-
mens into the prescription order for chemotherapy regimens 
or by proposing the prescription of antiemetic drugs to phy-
sicians. Adherence to the Japanese antiemetic guideline in 
both acute and delayed periods was evaluated. In the case 
of the dose of dexamethasone, the guideline recommends 
8 mg/day in the delayed period for HEC and MEC. In the 
present study, however, 4 mg/day on days 2–3 for MEC was 
regarded as positive for adherence because previous findings 
indicated that the control of delayed nausea is improved by 
20 % by the addition of 4 mg/day of dexamethasone on days 
2–3, when compared with no treatment with dexamethasone 
in patients receiving MEC [14].
Evaluation of chemotherapy‑induced nausea
All patients were provided with a checklist for daily 
check of adverse events on their first visit to the outpatient 
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chemotherapy clinic. Using the checklist, patients checked 
daily their nausea by numeric rating scale (0–10) and the 
number of vomiting episodes up to 7 days after chemother-
apy. Pharmacists and nurses recorded the control of nausea 
and vomiting on the electronic medical record after veri-
fying the data or hearing results from patients on the next 
visit. Complete protection from nausea (NRS scale <1) 
and vomiting (no episode) during acute (within 24 h after 
chemotherapy) and delayed (during 2–7 days after chemo-
therapy) periods was assessed in patients receiving the first 
cycle of chemotherapy or in those with overall cycles of 
chemotherapy.
Risk analysis for chemotherapy‑induced nausea 
during overall period
Demographics of patients were compared between patients 
who revealed acute and delayed nausea and those who 
showed complete protection from nausea. Subsequently, 
uni- as well as multivariate logistic regression analy-
ses were carried out to determine the risk for incomplete 
protection from for nausea or vomiting during the overall 
period. Odds ratio (OR) and 95 % confidence interval (CI) 
were determined. The cutoff value of age was determined 
by the Youden index or the distance method in the receiver 
operating characteristic curve (ROC) analysis. In the 
Youden index, cutoff age was estimated from the maximum 
value of (sensitivity + specificity − 1), whereas in the dis-
tance method, cutoff value was predicted from the mini-
mum value for square root [(1−sensitivity)2 + (1−specific-
ity)2)], according to the method described earlier [17, 18].
Statistical analyses
Data were analyzed using IBM SPSS Statistics ver. 22 
(IBM Japan Services, Tokyo, Japan) and Graph Pad Prism 
version 6.0 (Graph Pad Software, San Diego, CA, USA). 
Parametric variables were analyzed using the t test, and 
nonparametric data were analyzed by the Mann–Whitney 
U test or the chi-square test. Multiple comparisons for 
the control of nausea and vomiting were carried out by 
Kruskal–Wallis test followed by Scheffe’s test. A P value 
less than 0.05 was considered statistically significant.
Results
Demographics of patients
Demographics of the patients are shown in Table 1. Seven 
hundred and seventy-nine patients received 5511 chem-
otherapy cycles during 2 years from January 2013 to 
December 2014 in our outpatient chemotherapy clinic. The 
average chemotherapy cycle was 8.3 cycles. The most com-
mon type of cancer was colorectal cancer (26 % of patients 
and 35 % of all chemotherapy cycles), followed by lung 
cancer (14 % and 12 %), breast cancer (14 % and 17 %), 
gastric cancer (13 % and 12 %), liver/gallbladder/pancreas 
cancer (10 % and 9 %), hematological cancer (9 % and 
5 %), gynecological cancer (6 % and 5 %), and head and 
neck cancer (3 % and 2 %). The emetic risk of the chemo-
therapy regimens included HEC (291 cycles, 5 %), MEC 
(2184 cycles, 40 %), low risk (2162 cycles, 39 %), and 
minimum risk (874 cycles, 16 %).
Control of nausea and vomiting
The rates of complete protection from nausea and vomit-
ing during acute and delayed periods in the first cycle and 
overall cycles are shown in Fig. 1. In the first cycle of 
chemotherapy, the rate of adherence to the Japanese clini-
cal practice guideline for prevention of CINV ranged from 
76 % (HEC) to 99 % (low risk). Under such a condition, 
patients receiving HEC showed poor control of nausea 
during acute and delayed periods, although vomiting was 
favorably controlled (83–85 % of complete protection). 
The rates of complete protection from acute and delayed 
nausea were 61 % and 44 %, respectively, for HEC, and 
87 % and 68 %, respectively, for MEC, in which the rates 
increased in a manner dependent on the emetic risk of the 
chemotherapy. In the overall cycles, the control of nausea 
in HEC was greatly improved, in which the complete pro-
tection from acute and delayed nausea was 77 % and 62 %, 
respectively.
Comparison of demographics between patients who 
showed no nausea and those with nausea
To determine the risk of chemotherapy-induced nausea, the 
demographics of patients were compared between those 
with and without complete protection from nausea in 608 
patients who received the first cycle of chemotherapy. As 
shown in Table 2, significant differences in gender, age, 
proportion of HEC/MEC and anthracycline/cyclophospha-
mide (A/C) regimen, and type of cancer were observed 
between the two groups. Females were more often affected 
(67 % vs. 48 %, P < 0.001), patient age was younger (56.7 
vs. 63.4 years), and the proportion of A/C regimen (18 % 
vs. 2 %, P < 0.001) and HEC/MEC (64 % vs. 36 %) in 
patients without complete protection from nausea. Moreo-
ver, the percentage of breast cancer patients was signifi-
cantly higher (31 % vs. 18 %, P < 0.001) in patients with 
nausea than those without it.
On the other hand, adherence to the antiemetic guide-
line was not different between the two groups (92.4 % vs. 
93.6 %, P = 0.755).
412 Int J Clin Oncol (2016) 21:409–418
1 3
Risks for chemotherapy‑induced overall nausea or 
vomiting
Because age was significantly different between patients 
with and without overall nausea, an ROC curve was plot-
ted for sensitivity versus 1−specificity. The area under 
the curve (AUC) was 0.658 (95 % CI, 0.607–0.709), 
indicating low accuracy prediction [17]. Using the ROC 
curve method, the cutoff age was predicted to be 58.5 
years old (Youden index, 72.4 % sensitivity vs. 55.9 % 
specificity) or 61.5 years old (distance method, 63.6 % 
sensitivity vs. 62.7 % specificity). Thus, the cutoff age 
was set to 60 years for nausea. For vomiting, AUC of 
ROC curve was 0.721 (95 % CI, 0.629–0.813), indicat-
ing moderate accuracy prediction [17]. ROC analysis 
indicated that the cutoff age was 49.5 years old (Youden 
index as well as distance method, 84.5 % sensitivity vs. 
56.4 % specificity). Thus, the cutoff age was set to 50 
years old for vomiting.
As presented in Table 3, multivariate analysis showed 
that four factors such as female gender (OR 1.615; 95 % 
CI, 1.022–2.552; P = 0.004), age under 60 years (OR 
2.303; 1.525–3.477; P < 0.001), inclusion of HEC/MEC 
(OR 2.321; 1.489–3.617; P < 0.001), and A/C regimen (OR 
4.955; 1.863–13.18; P = 0.001) were significant risks for 
overall nausea.
On the other hand, female gender (OR 3.151; 95 % CI, 
1.213–8.183; P = 0.018), age under 50 years (OR 5.803; 
2.667–12.63, P < 0.001), and inclusion of HEC/MEC (OR 
2.993; 1.245–7.195; P = 0.014) were found to be signifi-
cant risks for overall vomiting by multivariate analysis. 
Adherence to the antiemetic guideline did not reduce the 
risk for overall nausea or vomiting (OR 0.960; 0.444–
2.076, P = 0.918 for nausea; OR 0.539; 0.138–2.110, 
P = 0.375 for vomiting).
Comparison of the control of nausea and vomiting 
among various HEC and MEC regimens
As risk analysis indicated that HEC/MEC and A/C regi-
men were significant risks for chemotherapy-induced 
nausea, the rates of complete protection from nausea and 
vomiting during acute and delayed periods were com-
pared among HEC and MEC regimens in patients who 
received the first cycle of chemotherapy. As shown in 
Fig. 2, the rate was significantly lower in A/C regimen 
(46 % and 24 % for acute and delayed periods, respec-
tively) as compared with other regimens, regardless 
Table 1  Demographics of 
patients Number of patients (male/female) 779 (391/388)
Age (average, min/max) 63.4 (18/88)
Body surface area (average, SD) 1.56 ± 0.40
Serum creatinine (mg/dl, average, SD) 0.72 ± 0.27
Number of chemotherapy courses 5511
Cancer type Number of patients % Number of courses %
Colorectal 201 25.8 1923 34.9
Lung 107 13.7 645 11.7
Breast 105 13.5 935 17.0
Gastric 101 13.0 680 12.3
Liver/gallbladder/pancreas 81 10.4 510 9.3
Hematological 73 9.4 270 4.9
Gynecological 49 6.3 259 4.7
Head and neck 26 3.3 117 2.1
Esophageal 15 1.9 49 0.9
Urological 10 1.3 89 1.6
Brain 9 1.2 25 0.5
Sarcoma 1 0.1 1 0.02
Dermatological 1 0.1 8 0.1
Average chemotherapy courses (min/max) 8.3 (1/91)
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of 100 % adherence to the guideline-recommended 
antiemetic medication. In contrast, the control of nausea 
was favorable for a cisplatin (CDDP)-containing regimen 
(94 % and 88 % for acute and delayed periods, although 
the dose of CDDP was low (25 mg/m2 in CDDP/gemcit-
abine for gallbladder cancer or 30 mg/m2 in CDDP/iri-
notecan for gastric cancer).
Change in the control of nausea and vomiting in A/C 
regimen after repeated treatment cycles
Although the complete protection from acute and delayed 
nausea in the first cycle of A/C chemotherapy was poor 
(46 % for acute nausea and 24 % for delayed nausea), 
the rates were improved in the second and third cycles of 
chemotherapy (Fig. 3). There were significant differences 
in the rates of delayed nausea and acute as well as delayed 
vomiting (Kruskal–Wallis test). On the other hand, dose 
reduction was not carried out in the first cycle in all 
patients but was performed in one patient in the second 
cycle (15 % reduction) as well as in the third cycle (15 % 
reduction).
Discussion
In the present study, we surveyed the rate of control of 
CINV in 779 patients who received 5511 cycles of chem-
otherapy regimens in our outpatient cancer chemotherapy 
clinic. Among them, patients with gastrointestinal cancer 
were predominant (51 % of patients and 57 % of chemo-
therapy cycles).
According to the clinical practice guidelines for antiem-
esis formulated by ASCO [4], MASCC/ESMO [5], NCCN 
[6], and JSCO [7], palonosetron, a long-acting second-
generation 5-HT3 receptor antagonist, is recommended 
for use in HEC and MEC; however, in the present study, 
the first generation of 5-HT3 receptor antagonists such as 
granisetron was predominantly prescribed. In the present 
study, health professionals, including pharmacists and 
nurses, interviewed all patients and monitored adverse 
drug reactions. In addition, we checked the prescription 
for antiemetic medication and aggressively promoted the 
appropriate use of antiemetic drugs. As a consequence, 
adherence to the clinical practice guideline for the use 
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Fig. 1  Complete protection from nausea and vomiting during acute 
and delayed periods in patients receiving high emetic risk chemother-
apy (HEC), moderate emetic risk chemotherapy (MEC), low risk, or 
minimum risk of chemotherapy as the first cycle or the overall cycles 
in the outpatient chemotherapy clinic. Adherence to the Japanese 
antiemetic guideline is shown at bottom. **P < 0.01 by Kruskal–Wal-
lis test followed by Scheffe’s test
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88 % for MEC, 99 % for low-risk) for patients receiving 
the first cycle of chemotherapy, except for those undergo-
ing CDDP-containing regimens (25 %). In the CDDP-
containing regimens used in the present study, the dose 
of CDDP was low (25–30 mg/m2); thus, aprepitant was 
excluded from the standard medication for HEC. Even such 
an antiemetic medication effectively prevented nausea and 
vomiting, in which the overall control rate was 88 % for 
nausea and 94 % for vomiting. Very recently, Tamura et al. 
[19] reported the effectiveness of the antiemetic guideline 
by a multi-institutional prospective observational study, 
showing that adherence to the guideline is approximately 
74 % for HEC and 95 % for MEC. They also reported 
that adherence (three antiemetics containing aprepitant, 
5-HT3 receptor antagonist, and dexamethasone) for HEC 
decreases the risk for delayed vomiting as compared with 
two antiemetics (5-HT3 receptor antagonist and dexametha-
sone) without marked influence on the control of nausea. 
In the present study, the rate of guideline consistency was 
generally consistent with the data reported by Tamura et al. 
[19], although the non-adherence did not affect the control 
of overall nausea or vomiting.
Under the condition of roughly consistent with guide-
line-recommended antiemetic medication, vomiting was 
fairly well controlled, but complete protection from nau-
sea was not sufficient for HEC and MEC. The poor control 
of nausea for HEC in the first cycle occurred primarily in 
the A/C regimen for breast cancer. Tamura et al. [19] also 
reported the high incidence of delayed nausea (49.4 % for 
HEC and 41.7 % for MEC), with a limited incidence of 
vomiting.
It was notable that the control of nausea and vomit-
ing was generally higher in the overall cycles than in the 
first cycle. Particularly, marked improvement of the con-
trol rate of delayed nausea was observed at the second 
and third cycles of A/C chemotherapy. It is unlikely that 
Table 2  Comparison of demographics of patients with nausea during overall period in 608 patients who received the first cycle of chemotherapy
a Chi-square test
b Mann–Whitney U test
c t test
With nausea during overall period (n = 158) Without nausea during overall period (n = 450) P
Ratio of female (female/male) 67.1 (106/52) 47.8 (215/235) <0.001a
Age (years) 56.7 (18–84) 63.4 (35–88) <0.001a
Height (cm) 160.1 ± 7.5 160.3 ± 8.5 0.775c
Body weight (kg) 55.0 ± 10.7 55.8 ± 10.8 0.464c
Serum creatinine (mg/dl) 0.69 ± 0.23 0.72 ± 0.23 0.170c
n % n % P
Regimens/anticancer drug
 A/C 28 17.7 9 2.0 <0.001a
 CHOP 3 1.9 5 1.1 0.733a
 Oxaliplatin 29 18.4 61 13.6 0.183a
 Irinotecan 17 10.8 35 7.8 0.323a
 Carboplatin 11 7.0 29 6.4 0.969a
 Cyclophosphamide 9 5.7 5 1.1 <0.001a
 Cisplatin (25–30 mg/m2) 2 1.3 14 3.1 0.338a
Emetic risk
 HEC + MEC 101 63.9 162 36.0 <0.001a
 Low + minimum 57 36.1 288 64.0
Cancer type
 Breast 49 31.0 81 18.0 <0.001a
 Colorectal 42 26.6 100 22.2 0.315a
 Lung 6 3.8 82 18.2 <0.001a
 Gastric 23 14.6 63 14.0 0.968a
 Liver/gall bladder/pancreas 10 6.3 48 10.7 0.150a
 Hematological 6 3.8 17 3.8 1.000a
 Gynecological 16 10.1 26 5.8 0.095a
 Adherence to antiemetic guideline 146 92.4 420 93.3 0.831a
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Table 3  Risk analysis for nausea and vomiting in 608 patients who underwent the first cycle of cancer chemotherapy
Univariate analysis Multivariate analysis
Odds ratio (OR) 95 % confidence interval P OR 95 % confidence interval P
Nausea
 Female 2.228 (1.524–3.258) <0.001 1.615 (1.022–2.552) 0.040
 Age < 60 years 3.007 (2.070–4.369) <0.001 2.303 (1.525–3.477) <0.001
 HEC/MEC 3.150 (2.160–4.595) <0.001 2.321 (1.489–3.617) <0.001
 A/C regimen 10.554 (4.857–22.93) <0.001 4.955 (1.863–13.18) 0.001
 Breast cancer 2.048 (1.354–3.098) 0.001 0.700 (0.375–1.306) 0.262
 Lung cancer 0.177 (0.076–0.415) <0.001 0.301 (0.125–0.725) 0.007
 Adherence to antiemetic guideline 0.869 (0.434–1.742) 0.692 0.960 (0.444–2.076) 0.918
Vomiting
 Female 4.429 (1.923–10.20) <0.001 3.151 (1.213–8.183) 0.018
 Age < 50 years 4.026 (1.997–8.117) <0.001 5.803 (2.667–12.63) <0.001
 HEC/MEC 4.152 (1.985–8.683) <0.001 2.993 (1.245–7.195) 0.014
 A/C regimen 8.205 (3.684–18.27) <0.001 2.987 (0.785–11.36) 0.108
 Breast cancer 2.777 (1.420–5.427) 0.003 0.527 (0.167–1.667) 0.276
 Lung cancer 0.304 (0.072–1.283) 0.105 0.759 (0.164–3.506) 0.724



























































































































Fig. 2  Comparison of the rates of complete protection from nau-
sea and vomiting among various chemotherapy regimens in patients 
receiving the first cycle of chemotherapy in the outpatient chemo-
therapy clinic. The number of patients (n) is shown in each pair of 
parentheses. Adherence to the Japanese antiemetic guideline during 
the overall period is represented at bottom of figure. Shaded columns 
represent HEC; open columns exhibit MEC. *P < 0.05, *P < 0.01 by 
Kruskal–Wallis test followed by Scheffe’s test
416 Int J Clin Oncol (2016) 21:409–418
1 3
improvement of the control of nausea results from decrease 
in the dose of anticancer drugs because, in the present 
study, the dose reduction was not observed in the first cycle 
but was carried out in one patient in the second cycle (15 % 
reduction) as well as in the third cycle (15 % reduction). 
Patients who showed failure in the control of CINV in the 
previous cycle were administered prochlorperazine or olan-
zapine in addition to an antianxiety drug such as lorazepam 
in the following cycles, which may be the predominant 
reason for the improvement of CINV control in the subse-
quent cycles. Moreover, in 608 patients who received the 
first cycle of HEC, MEC, low, or minimal risk of chemo-
therapy, the dose intensity was quite similar between 
patients with and without complete protection from nausea, 
in which the values were 97.0 ± 8.1 % (mean ± SD) in 
450 patients who showed complete protection from nausea 
and 97.0 ± 7.5 % in 158 patients who did not. In addition, 
the complete protection from nausea was 71.4 % (60 of 84 
patients) in patients with dose reduction and 74.4 % (390 
of 524 patients) in those without dose reduction (P = 0.654 
by χ2 test). Therefore, it is unlikely that the dose of anti-
cancer drugs affected the control of chemotherapy-induced 
nausea in the present study.
Several investigators have shown the risk factors for 
CINV. Female gender, age, no history of drinking, and his-
tory of hyperemesis gravidarum are common as risks that 
lead to a loss of control of CINV [19–26]. Sekine et al. [21] 
showed in patients receiving HEC or MEC that female gen-
der has high risk (OR 2.49) for failure in complete response 
(no vomiting and no rescue). It has also been reported that 
female patients are more likely to experience nausea and 
vomiting than male patients receiving HEC or MEC [22, 
23]. On the other hand, Hesketh et al. [24] reported in 
patients receiving CDDP (≥70 mg/m2) that females are at 
high risk for the inability to complete response (OR 1.303) 
only when aprepitant is not included in the antiemetic medi-
cation. Younger age is also a risk for the loss of emetic con-
trol, but the cutoff age differs among studies, ranging from 
40 to 65 years old [20–23]. Tamura et al. [19] also reported 
that older age is a decreased risk for CINV. However, the 
cutoff value of age that influences the control of CINV is 
still unclear. In the present study, the cutoff value of age was 
estimated from the ROC curve method, in which the AUC 
was 0.658 for nausea (low accuracy prediction) and 0.721 
for vomiting (moderate accuracy prediction). The cutoff 
age was 58.5 years old as determined by the Youden index 
or 61.5 years old by the distance method and was set at 60 
years old. Interestingly, the cutoff age for vomiting pre-
dicted by Youden index and distance method (49.5 years 
old) was younger than that for nausea. As a consequence, 
age under 60 years old was a significant risk for nausea 
(OR 2.303; 95 % CI, 1.525–3.477, P < 0.001), whereas 
age under 50 years old was a significant risk for vomiting 
(OR 5.803; 95 % CI, 2.667–12.63, P < 0.001). In addition, 
female gender (OR 1.615; 1.022–2.552, P = 0.04 for nau-
sea; OR 3.151; 1.213–8.183, P = 0.018 for vomiting) and 
HEC/MEC (OR 2.321; 1.489–3.617, P < 0.001 for nau-
sea; OR 2.993; 1.245–7.195, P = 0.014 for vomiting) were 
also significant risks for nausea or vomiting, although A/C 
chemotherapy was a significant risk for nausea but not for 
vomiting (OR 4.955; 1.863–13.18, P = 0.001). Our present 
findings indicating the difference in the cutoff age between 
nausea and vomiting suggest that the differences in the cut-
off age among studies may result from different indices of 
the control of CINV, including complete response, complete 
control, and complete protection from nausea or vomiting.
These findings, taken together, suggested that exten-
sive antiemetic medication using other types of antiemetic 
drugs such as olanzapine in addition to the standard medi-
cation is required for prevention of chemotherapy-induced 
Fig. 3  Change in the control of 
nausea and vomiting in patients 
receiving three consecutive 
cycles of anthracycline/cyclo-
phosphamide (A/C) regimen. 
*P < 0.05, *P < 0.01 by 
Kruskal–Wallis test followed by 
Scheffe’s test
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nausea in patients who possess risks for poor control of 
CINV, including being female, younger age, and A/C 
chemotherapy.
In the present study, no marked difference in the control 
of CINV among MEC except for cyclophosphamide-base 
regimens other than the A/C regimen, although there was 
a marked difference in the control of CINV among HEC, 
as mentioned earlier. The low rate of the control of CINV 
for cyclophosphamide-base regimens may be caused by the 
patient risks (female and young age) rather than the chem-
otherapy, because the cyclophosphamide-base regimens 
were used for the most part in breast cancer patients, whose 
average age was 48 years.
In conclusion, the control of CINV was investigated 
in 779 patients receiving 5511 cycles of chemotherapy 
regimens in our outpatient cancer chemotherapy clinic. In 
spite of the high rate of adherence to the antiemetic guide-
line, the control of nausea, but not vomiting, was poor in 
patients receiving HEC and MEC. A multivariate logistic 
regression analysis indicated that female gender, age under 
60 years, HEC/MEC, and A/C chemotherapy were signifi-
cant risks for overall nausea. Care should be taken to pre-
vent chemotherapy-induced nausea in high-risk patients.
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